Large-Cell Lymphoma
Seattle Genetics Reports Positive Phase I Data with SGN-35 in Hodgkin Lymphoma
Published in Genetics and Environmental Law Weekly, November 24th, 2007
Seattle Genetics, Inc. (Nasdaq: SGEN) announced positive data from an ongoing phase I trial of SGN-35, a proprietary antibody-drug conjugate (ADC) product candidate. Multiple objective responses have been observed at well-tolerated doses of SGN-35 in patients with relapsed or refractory Hodgkin lymphoma and other CD30-positive malignancies. The data were reported at the 7th International Symposium on Hodgkin Lymphoma in Cologne, Germany.
More than 75 percent of patients treated in the study achieved tumor reductions across all dose levels evaluated, including four with partial responses. Twelve additional patients had stable disease and seven had progressive disease. Of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Law Weekly
More Articles from Genetics and Environmental Law Weekly
- Acanthosis Nigricans
New findings reported from L. Arnaud-López and co-authors describe advances in acanthosis nigricans - Acute Leukemia
Data from University of Minnesota, Department of Pediatrics provide new insights into acute leukemia in children - Alexander Disease Genetics
Investigators at G. Gaslini Institute zero in on Alexander disease genetics - Amyotrophic Lateral Sclerosis Genetics
Researchers at Beaumont Hospital, Department of Neurology publish new data on amyotrophic lateral sclerosis genetics - Amyotrophic Lateral Sclerosis Risk Factors
New amyotrophic lateral sclerosis risk factors research from University of Oxford discussed - Anatomy
National Yang-Ming University, Institute of Anatomy and Cell Biology describes research in anatomy - More from this issue of Genetics and Environmental Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
